Lily’s ACTIV2 Clinical Trial for Bamlanivimab is now running in virtually every state in the nation. Adults 18 and older can enroll directly to help demonstrate the efficacy and safety of their monoclonal antibodies for both treatment and prevention.
immunoprevention.org/activ2-…
2
Glad to see the media increasingly picking up on this story. There SHOULD be a shortage because these are the first effective treatments that can help to prevent severe disease or death in the midst of an epic wave of infections.
immunoprevention.org/npr-low…
There is still tragic confusion and hesitation on the user of Monoclonal Antibodies despite clear communications from national health leaders and knowledgeable physicians that these therapeutics will save lives with early use.
immunoprevention.org/continu…
At last the obvious and critical information about antibodies are being clearly communicated - in this case by Commissioners Azar (HHS) and Hahn (FDA). Perhaps they will even start talking about prevention.
immunoprevention.org/cnn-mon…
Former FDA Commissioner Gottlieb continues to lead the call to scale production and use of antibodies as rapidly as possible.
Antibody therapies were our best bet to lower the Covid death rate this fall, but our stockpile wasn’t enough. We need to change that, writes @ScottGottliebMD on.wsj.com/3nguTjl
While the epidemic rages, insiders and VIPs are receiving antibody therapeutics, and states are implementing lotteries for the lucky few. WHY are supplies limited, and WHAT can we do about that? The answer is a LOT - if we have focus and action.
immunoprevention.org/antibod…
Some highlights of Operation Warp Speed “Playbook” for monoclonal antibody therapeutics, and what else is urgently needed to actually make this effective to keep people OUT of hospitals and save lives.
immunoprevention.org/operati…
#COVIDー19 #Antibodies #immunoprevention
Unfortunately, the guidelines published by the NIH’s COVID-19 Treatment Panel on November 18th appear to be creating caution and confusion around the opportunity these therapies represent, rather than the urgency and action they deserve.
immunoprevention.org/nih-sta…
Stand and be heard, or forever carry the shame.
While the president has the right to legitimate legal challenges, responsible citizens cannot let the reckless actions by him and his legal team stand. Republicans have an obligation when the subject is of such importance to challenge demagoguery and patently false statements.
FDA issued EUA for Eli Lilly's bamlanivimab yesterday, monoclonal antibody therapy for early treatment of patients who are 12 years of age and older, or 65 years of age or older, who have high risk for severe COVID-19 and/or hospitalization.
immunoprevention.org/fda-app…
While the virus surges, with hospitalizations and deaths to follow, antibody-based therapeutics have proven they can be game changers for both treatment and prevention. How much longer will our leaders fiddle while the country burns?
immunoprevention.org/fauci-w…
Regeneron publishes Phase 2/3 Trial results for REGN-COV2 showing it is a game changer for high risk adults with early stage COVID-19. For people with the highest risk factors, it reduced progression to severe illness by 72%.
immunoprevention.org/regener…
#COVID19 #immunoprevention
Feds purchase of 300K doses of Eli Lilly for bamlanivimab (LY-CoV555) marks another major milestone and vote of confidence for antibody drugs and therapeutics to turn the tide in the war on COVID-19.
immunoprevention.org/feds-pu…
#covid #monoclonalantibodies #immunoprevention
While the epidemic surges with no end in sight, one thing is certain: antibody-based therapeutics remain grossly underfunded and underprioritized.
immunoprevention.org/while-e…
#antibodies #monoclonalantibodies #covid #immunoprevention
What Does the Eli Lilly ACTIV-3 Trial Results Mean for Antibody Treatments? Prevention and Protection Should Be the Focus. There was rarely a case where the old maxim was more true: an ounce of prevention is worth a pound of cure.
immunoprevention.org/what-do…
AstraZeneca has received $486M to accelerate both Phase 3 Trials and production for their long-acting antibody (LAAB) combination, AZD7442.
immunoprevention.org/astraze…
Breakthrough antibody-based drugs will become available but in very short supply in Q4. If you are a business or community leader that has responsibility and concern for front line workers and vulnerable populations, here is what you can do now.
immunoprevention.org/antibod…
How Antibodies Help Your Body Beat COVID-19
immunoprevention.org/chartin…
President's Trump's illness and treatment can be national "learning moment" for how and why antibody based drugs are a crucial tool to turn the tide on COVID-19.
immunoprevention.org/dr-davi…







